Gilead Sciences, Inc. (NASDAQ:GILD) to Issue Quarterly Dividend of $0.82

Gilead Sciences, Inc. (NASDAQ:GILD) declared a quarterly dividend on Tuesday, February 10th. Shareholders of record on Friday, March 13th will be given a dividend of 0.82 per share by the biopharmaceutical company on Monday, March 30th. This represents a c) dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Friday, March 13th. This is a 3.8% increase from Gilead Sciences’s previous quarterly dividend of $0.79.

Gilead Sciences has increased its dividend payment by an average of 0.0%annually over the last three years and has raised its dividend annually for the last 10 consecutive years. Gilead Sciences has a dividend payout ratio of 37.1% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Gilead Sciences to earn $8.11 per share next year, which means the company should continue to be able to cover its $3.16 annual dividend with an expected future payout ratio of 39.0%.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD traded up $8.94 during trading on Wednesday, reaching $156.17. The company had a trading volume of 7,754,233 shares, compared to its average volume of 7,844,875. The company has a fifty day moving average of $128.39 and a two-hundred day moving average of $121.53. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $193.76 billion, a P/E ratio of 24.21, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36. Gilead Sciences has a 12 month low of $93.37 and a 12 month high of $157.29.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion during the quarter, compared to analyst estimates of $7.68 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Equities research analysts forecast that Gilead Sciences will post 7.95 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.